Last updated: 2026-10-18 01:36:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Eupraxia Pharmaceuticals Inc. (EPRX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $6.62, with a market capitalization of $447.32M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.25 to $9.32. This page covers its latest market performance, valuation, price trends and company information.
$447.32M | |
$6.78 | |
$9.32 | |
$2.20 | |
$6.77 | |
568.48K | |
633.92K | |
-- | |
$9.32 | |
$5.25 | |
-- | |
-- |
Eupraxia Pharmaceuticals Inc. (EPRX) last closed at $6.77 as of 2026-10-16 23:31:00, unchanged from the previous close of $6.77.
During the latest regular trading session, EPRX traded between $2.20 and $9.32, with a volume of 568.48K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Eupraxia Pharmaceuticals Inc. (EPRX) moved from $7.57 to $6.62, representing a decline of 12.55% ($0.95).
The stock traded between $6.42 and $7.75 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 702.71 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 33.7%
EPRX is currently trading at $6.62, placing it 33.7% of the way from its 52-week low of $5.25 to its 52-week high of $9.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
| Employees | 49 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Eupraxia Pharmaceuticals Inc. (EPRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.